A major lung-disease research update for patients across the United States: Bristol Myers Squibb says its experimental drug admilparant met the main goal in a Phase 3 trial for idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring.

Announced on October 12, ...Read morethe results showed that the 60 mg dose significantly improved the change in forced vital capacity (FVC)—a measure of how much air a person can exhale—compared with placebo after 52 weeks. The higher, 120 mg dose did not reach statistical significance.

#LungDisease #USHealthNews #MedicalResearch — The findings could move researchers closer to another potential treatment for people living with IPF, which can gradually reduce lung function and make everyday activities more difficult.

Admilparant remains investigational and is not yet approved. Bristol Myers Squibb says detailed results will be presented at a future medical meeting, so the size of the benefit still needs closer review.

A new development in cancer research could matter for patients across the United States and Canada living with rare, advanced neuroendocrine tumors of the digestive system.

On October 12, Bristol Myers Squibb announced positive Phase 3 results for RYZ101, an experimental targeted ...Read moreradiopharmaceutical treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The ACTION-1 trial met its primary goal, showing a statistically significant improvement in the time patients lived without their cancer progressing compared with standard treatment options.

#CancerResearch #USHealthNews #CanadaHealth — The findings are especially relevant to patients whose tumors progressed after earlier lutetium-177-based treatment and who may have limited options remaining.

RYZ101 is not yet FDA-approved. The company has not released detailed trial results, and further regulatory discussions are planned. The findings are encouraging, but more information is needed to understand the size of the benefit and its impact on overall survival.

A new treatment option is now available for certain immunocompromised adults in the United States dealing with persistent herpes simplex virus (HSV) lesions that have not responded to standard antiviral medicines.

On October 9, the U.S. Food and Drug Administration approved Hovilpri ...Read more(pritelivir) for eligible adults whose HSV lesions have not responded to medicines such as acyclovir, valacyclovir, or famciclovir.

#FDAApproval #USHealthNews #MedicalNews In the Phase 3 clinical trial, all lesions had healed by day 28 in 63% of patients receiving Hovilpri, compared with 34% receiving other selected treatments. The approval gives patients with weakened immune systems another option for a difficult-to-treat infection.

Hovilpri does not cure HSV and is not intended for everyone with herpes. Its approval applies to a specific group of immunocompromised adults with treatment-refractory lesions.

United States: the FDA has approved a new treatment combination for certain people with stage III colon cancer.

On October 8, the U.S. Food and Drug Administration approved atezolizumab, also known as Tecentriq, alongside chemotherapy for eligible patients whose tumors have a specific ...Read moreDNA-repair deficiency. The clinical trial included 712 patients and found a significant improvement in disease-free survival compared with chemotherapy alone.

#ColonCancer #FDAApproval #USHealthNews — This approval could give eligible American patients and their oncology teams another option after surgery to help reduce the risk of cancer returning.

It is not intended for every colon cancer patient. Eligibility depends on the tumor’s specific characteristics and the treatment plan determined with a qualified cancer specialist.

The FDA has approved a new combination treatment for adults with advanced HER2-positive breast cancer that cannot be removed with surgery or has spread to other parts of the body.

Approved on October 7, the regimen combines tucatinib with trastuzumab and pertuzumab as maintenance treatment...Read more after initial therapy. The goal is to help keep the cancer from progressing for longer.

#BreastCancer #CancerResearch #MedicalNews — In the HER2CLIMB-05 clinical trial, patients receiving the tucatinib combination had a median of 24.9 months without disease progression, compared with 16.3 months for those receiving the comparison regimen.

This is an additional option for eligible patients, not a cure or a treatment for every type of breast cancer. The FDA also highlights important safety risks, including potential liver toxicity.

A former New York podiatrist has been sentenced to 32 months in prison for his role in an approximately $11 million healthcare fraud scheme targeting Amtrak’s employee health plan.

Michael DeNicola also received a sentence related to separate drug-distribution and firearm offenses. The ...Read morecourt ordered him to pay more than $1.6 million in restitution.

#HealthcareFraud #Amtrak #MedicareNews — The Justice Department says the wider scheme involved false claims for services that were never provided or were medically unnecessary, with healthcare providers paying kickbacks to employees in exchange for using their insurance information.

The case shows that employer-sponsored health plans can also suffer major losses from healthcare fraud.

A doctor has been sentenced to three years in prison in a healthcare fraud case involving more than $40 million in claims tied to telemedicine and kickback schemes.

Le Thu, a 71-year-old physician from Boston, was sentenced on October 6 for her role in schemes involving Medicare and ...Read moreTRICARE. The court also ordered her to pay more than $27 million in restitution.

#MedicareFraud #TRICARE #HealthcareNews — Telemedicine can make care more accessible, but federal investigators say improper kickbacks and questionable medical orders can turn remote healthcare arrangements into costly fraud schemes.

The case highlights the importance of ensuring medical decisions are based on patients’ genuine healthcare needs.

🚨 A federal jury convicted a former Florida laboratory vice president and marketing company operator in a Medicare fraud scheme involving more than $15 million in claims.

Prosecutors said people who signed up for COVID-19 tests during the pandemic were also given additional blood tests ...Read morethey didn’t want or need. The extra tests were allegedly billed to Medicare as medically necessary, even though no treating doctor had ordered them.

#MedicareFraud #COVID19 #HealthcareNews — The scheme involved nearly 2,000 patients at nine residential clubs over about four months. Medicare was billed more than $15 million and paid over $500,000, according to the Justice Department.

The case highlights how healthcare fraud can exploit vulnerable people during a public health emergency.

🚨 A smart ring can now track blood pressure continuously without an inflatable cuff. Happy Health’s Happy Ring received FDA clearance for cuffless, calibration-free blood pressure monitoring, allowing readings to be collected throughout the day and night.
#BloodPressure #WearableTech ...Read more#MedicalNews — The technology could help clinicians understand blood-pressure patterns that occasional measurements may miss. High blood pressure is a major risk factor for heart disease and stroke, making continuous monitoring a potentially important development.
However, FDA clearance applies to the device’s authorized use. It does not mean users should replace medical advice or prescribed monitoring with a wearable